Effect of nifedipine monotherapy on platelet aggregation in patients with untreated essential hypertension. 1990

Z Ośmiałowska, and M Nartowicz-Słoniewska, and J M Słomiński, and B Krupa-Wojciechowska
Department of Diagnostic Laboratory, Medical Academy, Gdańsk, Poland.

The effect of 6 weeks of nifedipine 30-60 mg/d on platelet aggregation and lipid parameters has been studied. A diminution in ADP-, adrenaline- and collagen-induced aggregation was observed. In the case of adrenaline- and collagen-stimulated aggregation the decrease was statistically significant. It was found that platelets which aggregated markedly during the placebo treatment were most strongly inhibited by nifedipine. The changes in lipid parameters were not significantly correlated with changes in aggregation.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008055 Lipids A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed) Lipid
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009543 Nifedipine A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure. Adalat,BAY-a-1040,Bay-1040,Cordipin,Cordipine,Corinfar,Fenigidin,Korinfar,Nifangin,Nifedipine Monohydrochloride,Nifedipine-GTIS,Procardia,Procardia XL,Vascard,BAY a 1040,BAYa1040,Bay 1040,Bay1040,Monohydrochloride, Nifedipine,Nifedipine GTIS
D010974 Platelet Aggregation The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS. Aggregation, Platelet
D010975 Platelet Aggregation Inhibitors Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. Antiaggregants, Platelet,Antiplatelet Agent,Antiplatelet Agents,Antiplatelet Drug,Blood Platelet Aggregation Inhibitor,Blood Platelet Antagonist,Blood Platelet Antiaggregant,PAR-1 Antagonists,Platelet Aggregation Inhibitor,Platelet Antagonist,Platelet Antagonists,Platelet Antiaggregant,Platelet Antiaggregants,Platelet Inhibitor,Protease-Activated Receptor-1 Antagonists,Antiplatelet Drugs,Blood Platelet Aggregation Inhibitors,Blood Platelet Antagonists,Blood Platelet Antiaggregants,Platelet Inhibitors,Agent, Antiplatelet,Aggregation Inhibitor, Platelet,Antagonist, Blood Platelet,Antagonist, Platelet,Antiaggregant, Blood Platelet,Antiaggregant, Platelet,Drug, Antiplatelet,Inhibitor, Platelet,Inhibitor, Platelet Aggregation,PAR 1 Antagonists,Platelet Antagonist, Blood,Platelet Antiaggregant, Blood,Protease Activated Receptor 1 Antagonists
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Z Ośmiałowska, and M Nartowicz-Słoniewska, and J M Słomiński, and B Krupa-Wojciechowska
November 2009, Journal of thrombosis and thrombolysis,
Z Ośmiałowska, and M Nartowicz-Słoniewska, and J M Słomiński, and B Krupa-Wojciechowska
April 2000, Journal of human hypertension,
Z Ośmiałowska, and M Nartowicz-Słoniewska, and J M Słomiński, and B Krupa-Wojciechowska
January 1986, Journal of cardiovascular pharmacology,
Z Ośmiałowska, and M Nartowicz-Słoniewska, and J M Słomiński, and B Krupa-Wojciechowska
January 1984, Journal of cardiovascular pharmacology,
Z Ośmiałowska, and M Nartowicz-Słoniewska, and J M Słomiński, and B Krupa-Wojciechowska
May 1988, Hypertension (Dallas, Tex. : 1979),
Z Ośmiałowska, and M Nartowicz-Słoniewska, and J M Słomiński, and B Krupa-Wojciechowska
January 1985, Acta medica Scandinavica,
Z Ośmiałowska, and M Nartowicz-Słoniewska, and J M Słomiński, and B Krupa-Wojciechowska
July 1986, International journal of clinical pharmacology, therapy, and toxicology,
Z Ośmiałowska, and M Nartowicz-Słoniewska, and J M Słomiński, and B Krupa-Wojciechowska
March 1994, Polskie Archiwum Medycyny Wewnetrznej,
Z Ośmiałowska, and M Nartowicz-Słoniewska, and J M Słomiński, and B Krupa-Wojciechowska
January 1988, European journal of clinical pharmacology,
Z Ośmiałowska, and M Nartowicz-Słoniewska, and J M Słomiński, and B Krupa-Wojciechowska
January 1993, Clinical therapeutics,
Copied contents to your clipboard!